Mallia JO, Singh N, Shah Ume-K, Jenkins GJS, Doak SH. Development of a novel in vitro 3D model to assess potential genotoxicity of nanomaterials. 38th Annual Meeting UKEMS, 12th -15th July 2015. Submitted to Mutagenesis.
Evans S, Singh N, Jenkins GJS, Doak SH. Secondary mechanisms of genotoxicity promoted by ultrafine superparamagnetic iron oxide nanoparticles via immune cell activation in vitro 38th Annual Meeting UKEMS, 12th -15th July 2015. Submitted to Mutagenesis.
Shah Ume-K, Mallia JO, Singh N, BéruBé K, Doak SH, Jenkins GJS. Optimization of three-dimensional (3D) in vitro model of HepG2 cells spheroids for genotoxicity testing, 38th Annual Meeting UKEMS, 12th -15th July 2015. Submitted to Mutagenesis.
Evans S, Singh N, Wills J, Monopoli M, Hondow N, Brown A, Wilkinson T, Jenkins GJS and Doak S Promotion of an immune response and genotoxicity by ultrafine superparamagnetic iron oxide as a result of their physico-chemical characteristics 38th Annual Meeting UKEMS , 12th -15th July 2015. Submitted to Mutagenesis.
Singh N, Haboubi H, Evans S, Nelson BC, Marquis BJ, Jenkins GJS, Doak SH Superparamagnetic iron oxide nanoparticles disrupt actin cytoskeleton and induce (geno)toxicity 38th Annual Meeting UKEMS , 12th -15th July 2015. Submitted to Mutagenesis.
Webb, R, Potter, S, Evans S. Doak SH and Singh, N. Fe2O3-SPION nanoparticles have only a transient effect on monocyte [Ca2+]I homeostasis, and this does not appear to be sufficient to impact upon either actin polymerisation or cell viability.Calcium Signalling: The Next Generation, Biochemical Society Conference (Oct, 9th 2014).
Singh N, Nelson BC, Jenkins GJS, Doak SH Role of oxidation state in guiding the fabrication of biocompatible superparamagnetic iron oxide nanoparticles- DNA damage & liver toxicity. 7th International Nanotoxicology Congress – NanoTOX 23-26 April 2014 in Antalya, Turkey.
Singh N, Kirkali G, Nelson BC, Dizdaroglu M, Jenkins GJS, Doak SH Potential Genotoxicity of Superparamagnetic Iron Oxide Nanoparticles – Role of DNA Repair Proteins. 36th Annual Meeting UKEMS , 15th -17th July 2013. Submitted to Mutagenesis.
Singh N, Jenkins GJS, Bryant N, Marquis B, Maffeis TGG, et al DNA Damaging Potential of Superparamagnetic Iron Oxide Nanoparticles. 35th Annual Meeting UKEMS, 16th July -18th July 2012. Mutagenesis vol. 27 no.6 pp.789-816.
Singh N, Jenkins GJS, Bryant N, Marquis B, Maffeis TGG, Williams PM, et al Iron Redox State: The Underlying culprit in the genotoxicity of ultrafine superparamagnetic iron oxide nanoparticles (USPION). Abstract 32, 34th Annual Meeting of UKEMS, 29th June -1st July 2011. Mutagenesis vol. 25 no. 6 pp. 631–658.
Griffiths SM, Singh N, Jenkins GJS, Doak SH “Dextran coated ultrafine superparamagnetic iron oxide nanoparticles: compatibility with common fluorometric and colourometric dyes” Abstract 34, 33rd Annual Meeting of UKEMS, 12th 14th July 2010. Mutagenesis vol. 25 no. 6 pp. 631–658.
Singh N, Asadi R, Griffiths SM, Jenkins GJS, Williams PM, Wright CJ, Doak SH. Understanding the in vitro genotoxicity induced by ultrafine superparamagnetic iron oxide nanoparticles (USPION). Abstract 32, 33rd Annual Meeting of UKEMS, 12th -14th July 2010. Mutagenesis vol. 25 no. 6 pp. 631–658, 2010.
Singh N, Bennet A, Jenkins GJS, Wright CJ, Doak SH “Cellular response and internalization of dextran-coated ultrasmall superparamagnetic iron oxide nanoparticles (USPION)” Abstract 48, 31st Annual Meeting of UKEMS, 15th 18th June 2010. Mutagenesis vol. 24 no. 1 pp. 97–114, 2009.
Manshian B, Singh N, Jenkins GJS, Barron A, et al Are single-walled carbon nanotubes the new asbestos? Abstract 43, 31st Annual Meeting of UKEMS, 15th -18th June 2010. Mutagenesis vol. 24 no. 1 pp. 97–114, 2009.
Griffiths SM, Singh N, Jenkins GJS, Doak SH “Iron oxide nanoparticles interact with fluorometric and colourometric dyes”, Abstract 88, NanoImpactNet Conference 23-27th March, Lausanne, Switzerland, 2009.
Singh N, Roberts A, Webb R, Thomas A et al. “Potential antiatherosclerotic effects of rosiglitazone via inhibition of actin polymerisation in monocytes-involvement of intracellular Ca2+ and Akt phosphorylation” 65th Annual Meeting of the American-Diabetes-Association, Jun 10-14, 2005 Diabetes 54: A37-A37, Suppl. 1 2005.
Singh N. Webb R., Adams R., Morris K, Evans M, et al (2005) “Rosiglitazone and the Microvasculature: the Roles of Akt Phosphorylation, Calcium Signalling and the Actin Cytoskeleton” Abstract 23, "3rd International Symposium on PPARs: From Basic Science to Clinical Applications", Monte Carlo Grand Hotel, Monaco, March 19-23, 2005.
Khanolkar M Morris K, Thomas A Roberts AW, Geen J, Singh N, Evans M “Antithrombotic properties of rosiglitazone in patients with type 2 diabetes independent of metabolic effects: A consequence of platelet PPAR gamma activation” 65th Annual Meeting of the American-Diabetes-Association, Jun 10-14, 2005 Diabetes 54: A135-A135, Suppl. 1 2005.
Khanolkar M, Thomas A, Singh N, et al. “Effects of rosiglitazone on platelet aggregation” 64th American-DiabetesAssociation, Jun 04-08, 2004, Diabetes 53: A132-A132, Suppl. 2 JUN 2004.
Lin T, Singh N, et al “The PPAR ligand, conjugated linoleic acid reduces expression of the receptor for advanced glycosylated end-products (RAGE) in monocytic cells” 2004, Mediators of inflammation, 13(1), 55-67.
Singh N, Morris K, Alan R, Aled R, Marc E, Thomas A, “Pioglitazone, but not the specific PPAR gamma agonist, GW7845, down regulates glycated protein induced cyclooxygenase-2 expression in human monocytes” 63rd Annual Meeting of the American-Diabetes-Association, Jun 13-17, 2003 Diabetes 52: A180-A180 Suppl. 1 2003.